Algeta's Phase II Pain Palliation Study Meets Endpoint
Posted on: Thursday, 28 August 2008, 09:01 CDT
Algeta ASA, the Norwegian cancer therapeutics company, has announced that its BC1-03 Phase II pain palliation study met its primary objective.
The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. The trial also confirmed Alpharadin's benign side-effect profile and, importantly for a drug in this clinical setting, no significant bone marrow toxicity was said to be observed.
The BC1-03 study was a double-blind randomized pain control study comparing the palliative effects of four different single dose levels of Alpharadin in patients with bony metastatic hormone refractory prostate cancer (HRPC). The drug was given by i.v. injection mainly on an outpatient basis.
The palliative efficacy of Alpharadin was measured using an assessment of bone pain as well as the patient's consumption of analgesia. The primary study objective was to investigate whether there was a dose-response relationship with respect to pain palliation in this patient group.
The study also showed a dose-dependent reduction in bone alkaline phosphatase (ALP) ranging from no effect in the lowest dose group to a marked reduction in the higher dose groups. ALP is said to be a severity marker of bony metastatic disease and of prognostic importance.
Thomas Ramdahl, Algeta's president and CEO, said: "These results build on the positive Phase II clinical data package that we have already assembled with Alpharadin, the highlight of which was the significant survival benefits that we have already reported in patients with HRPC."
Source: Datamonitor
Related Articles
- Aeolus Pharmaceuticals Announces Initiation of Multiple Dose Study of AEOL 10150 in a Patient With ALS
- Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
- EarlySense Receives FDA Clearance for Its Contact-Free Patient's Clinical Status Monitor
- MEDecision's Patient Clinical Summary To Be Implemented By Memphis Managed Care Corporation
- New Phase IV Clinical Study Indicates LidoSite(R) Provides Rheumatology Patients Superior Pain Relief
- ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients
- Clofarabine European Study Confirms Efficacy in Pediatric Patients With Acute Lymphoblastic Leukemia; Study Update at American Society of Hematology
- Amarin Reports Initiation of Enrollment and First Patient Dosing in Pivotal Phase III Clinical Trials for Miraxion in Huntington's Disease
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
- The Role of Whole-Body Bone Scanning and Clinical Factors in Detecting Bone Metastases in Patients With Non-Small Cell Lung Cancer*
 |
 |
User Comments (0)
RSS Feeds